MARKET

MRTX

MRTX

Mirati
NASDAQ

Real-time Quotes | Nasdaq Last Sale

90.98
+1.65
+1.85%
After Hours: 90.98 0 0.00% 16:36 01/24 EST
OPEN
90.53
PREV CLOSE
89.33
HIGH
92.73
LOW
89.81
VOLUME
726.73K
TURNOVER
--
52 WEEK HIGH
132.59
52 WEEK LOW
55.11
MARKET CAP
3.90B
P/E (TTM)
-19.4145
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MRTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MRTX News

  • H.C. Wainwright Reiterates Buy on Mirati Therapeutics, Raises Price Target to $134
  • Benzinga.2d ago
  • Better Buy: Exact Sciences vs. Qiagen
  • MotleyFool.com.3d ago
  • Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
  • PR Newswire.01/14 21:01
  • Dow's vies for 29,000 close, JP Morgan healthcare, bank earnings: 3 things to watch for Monday
  • CNBC.com.01/10 21:25

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About MRTX

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
More

Webull offers Mirati Therapeutics Inc (MRTX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.